<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00381940</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-01063</org_study_id>
    <secondary_id>NCI-2009-01063</secondary_id>
    <secondary_id>CDR0000500142</secondary_id>
    <secondary_id>AHOD0521</secondary_id>
    <secondary_id>AHOD0521</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT00381940</nct_id>
    <nct_alias>NCT01648439</nct_alias>
  </id_info>
  <brief_title>Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy</brief_title>
  <official_title>A Phase II Study of Bortezomib (Velcade, PS-341) in Combination With Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults With Refractory/Recurrent Hodgkin Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and efficacy of bortezomib with ifosfamide and&#xD;
      vinorelbine in children and young adults with Hodgkin's lymphoma that was recurrent or did&#xD;
      not respond to previous therapy. Bortezomib is an inhibitor of protein degradation.&#xD;
      Bortezomib degrades short-lived regulatory proteins in the cell, and has been reported to&#xD;
      increase the tumor cells. Bortezomib may increase the effectiveness of ifosfamide and&#xD;
      vinorelbine (two standard drugs given to children with Hodgkin Lymphoma that has come back&#xD;
      after initial treatment) by making cancer cells more sensitive to effectiveness of standard&#xD;
      chemotherapy by preventing anti-death responses in these drugs. Giving bortezomib together&#xD;
      with ifosfamide and vinorelbine tartrate should kill more cancer cells than are killed with&#xD;
      ifosfamide and vinorelbine alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy and safety of bortezomib (as a chemosensitizing agent) in pediatric&#xD;
      patients and young adults with primary refractory Hodgkin's lymphoma (HL) or HL in first&#xD;
      relapse.&#xD;
&#xD;
      II. Determine the response rate in patients treated with bortezomib, ifosfamide, and&#xD;
      vinorelbine ditartrate (vinorelbine tartrate) (IVB) and compare the response rate to the&#xD;
      historical response rate in patients treated with ifosfamide and vinorelbine ditartrate&#xD;
      alone.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the overall response rate (complete and partial response) and induction success&#xD;
      rate after 2 or 4 courses of therapy and the reinduction rate (complete response) after 4&#xD;
      courses of therapy.&#xD;
&#xD;
      II. Determine the proportion of patients able to mobilize sufficient hematopoietic stem cells&#xD;
      (CD34+) after 2 courses of IVB.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open-label, pilot study.&#xD;
&#xD;
      Patients receive ifosfamide intravenously (IV) continuously over days 1-4, vinorelbine&#xD;
      tartrate IV over 6-10 minutes on days 1 and 5, and bortezomib intravenously on days 1, 4, and&#xD;
      8, and filgrastim (G-CSF) by vein or subcutaneously beginning on day 6 and continuing until&#xD;
      blood counts recover or peripheral blood stem cells (PBSC) are harvested. Treatment cycles&#xD;
      repeat every 21 days for up to 2 or 4 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients undergo autologous PBSC harvesting according to institutional guidelines after the&#xD;
      second course of therapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 months for 2 years and&#xD;
      then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response (CR)</measure>
    <time_frame>After 2 cycles of treatment</time_frame>
    <description>CR is defined as at least 80% reduction in the sum of the products of the perpendicular diameters of each of the nodal masses or return to normal size, along with negative nuclear medicine imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 3 or 4 Toxicity</measure>
    <time_frame>4 weeks following completion of therapy</time_frame>
    <description>Grade 3 and 4 non-hematologic toxicity during protocol therapy. The number of patients that experience CTC Version 4 grade 3 or higher non-hematologic at any time during protocol therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>After 2 cycles and 4 cycles</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Success Rate</measure>
    <time_frame>After 2 cycles and 4 cycles</time_frame>
    <description>Induction success is defined as achieving CR or PR without a targeted primary toxicity. Primary toxicity includes toxic death (which is any death predominantly attributable to treatment-related toxicities or complications, occurring during or within one month of the completion of therapy), Non-hematologic grades 3 or 4 toxicities attributable to drug (with the specific exclusion of 1) Grade 3 or 4 nausea or vomiting, 2) grade 3 transaminases (AST/ALT) elevations which return to &lt; grade 1 prior to the time of the next treatment course, 3) grade 3 or 4 fever or infection, and 4) Grade 3 mucositis.) and Hematologic toxicity (Delay of &gt;2 weeks in the start of re-induction cycle 2 or in hematologic recovery after cycle 2 secondary to severe myelosuppression, infection, or sepsis.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Successful PBSC Harvest</measure>
    <time_frame>After 2 cycles</time_frame>
    <description>Success is defined as the ability to harvest 2x10^6 CD34+ cells/kg within 5 collection days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological Markers</measure>
    <time_frame>Before, during, and after treatment</time_frame>
    <description>Assessing baseline NF-kB protein levels in tumor tissue</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Adult Lymphocyte Depletion Hodgkin Lymphoma</condition>
  <condition>Adult Lymphocyte Predominant Hodgkin Lymphoma</condition>
  <condition>Adult Mixed Cellularity Hodgkin Lymphoma</condition>
  <condition>Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma</condition>
  <condition>Adult Nodular Sclerosis Hodgkin Lymphoma</condition>
  <condition>Childhood Lymphocyte Depletion Hodgkin Lymphoma</condition>
  <condition>Childhood Lymphocyte Predominant Hodgkin Lymphoma</condition>
  <condition>Childhood Mixed Cellularity Hodgkin Lymphoma</condition>
  <condition>Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma</condition>
  <condition>Childhood Nodular Sclerosis Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent/Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Stage I Adult Hodgkin Lymphoma</condition>
  <condition>Stage I Childhood Hodgkin Lymphoma</condition>
  <condition>Stage II Adult Hodgkin Lymphoma</condition>
  <condition>Stage II Childhood Hodgkin Lymphoma</condition>
  <condition>Stage III Adult Hodgkin Lymphoma</condition>
  <condition>Stage III Childhood Hodgkin Lymphoma</condition>
  <condition>Stage IV Adult Hodgkin Lymphoma</condition>
  <condition>Stage IV Childhood Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (enzyme inhibitor therapy, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ifosfamide IV continuously over days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, bortezomib IV on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy, chemotherapy)</arm_group_label>
    <other_name>Cyfos</other_name>
    <other_name>Holoxan</other_name>
    <other_name>IFF</other_name>
    <other_name>IFX</other_name>
    <other_name>IPP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy, chemotherapy)</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy, chemotherapy)</arm_group_label>
    <other_name>Eunades</other_name>
    <other_name>navelbine ditartrate</other_name>
    <other_name>NVB</other_name>
    <other_name>VNB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given IV or SC</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy, chemotherapy)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed Hodgkin's lymphoma at time of relapse or disease progression,&#xD;
             meeting all of the following criteria:&#xD;
&#xD;
               -  Stage I-IV disease&#xD;
&#xD;
               -  No morphologically unclassifiable disease&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Mixed cellularity&#xD;
&#xD;
               -  Lymphocytic depletion (LD)&#xD;
&#xD;
               -  LD, diffuse fibrosis&#xD;
&#xD;
               -  LD, reticular&#xD;
&#xD;
               -  Lymphocyte predominance (LP)&#xD;
&#xD;
               -  LP, diffuse&#xD;
&#xD;
               -  LP, nodular&#xD;
&#xD;
               -  Nodular sclerosis (NS)&#xD;
&#xD;
               -  NS, cellular phase&#xD;
&#xD;
               -  NS, lymphocytic predominance&#xD;
&#xD;
               -  NS, mixed cellularity&#xD;
&#xD;
               -  NS, LD&#xD;
&#xD;
               -  Not otherwise specified&#xD;
&#xD;
          -  Primary refractory disease OR disease in first relapse, except for the following:&#xD;
&#xD;
               -  Patients who achieved a complete response after treatment on protocol&#xD;
                  COG-AHOD0431 who experience a biopsy-proven recurrence after doxorubicin&#xD;
                  hydrochloride, vincristine, prednisone, and cyclophosphamide without&#xD;
                  involved-field radiotherapy&#xD;
&#xD;
               -  Patients on the observation-only arm of protocol COG-AHOD0431&#xD;
&#xD;
          -  Any measurable, focal mass lesion of a visceral organ (e.g., liver, spleen, or kidney)&#xD;
&#xD;
          -  Patients with metastatic disease to bone marrow and granulocytopenia, anemia, and/or&#xD;
             thrombocytopenia are allowed provided both of the following criteria are met:&#xD;
&#xD;
               -  Platelet count ≥ 20,000/mm³ (platelet transfusion allowed)&#xD;
&#xD;
               -  Hemoglobin ≥ 8 g/dL (packed red blood cell transfusion allowed)&#xD;
&#xD;
          -  Karnofsky performance status (PS) 60-100% (for patients &gt; 16 years of age) OR Lanksy&#xD;
             PS 60-100% (for patients =&lt; 16 years of age)&#xD;
&#xD;
          -  Life expectancy &gt;= 2 months&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 75,000/mm^3 (transfusion independent) (for patients with no bone&#xD;
             marrow involvement)&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate &gt;= 70 mL/min/1.73 m^2&#xD;
&#xD;
          -  AST and ALT =&lt; 2.5 times ULN&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 times ULN&#xD;
&#xD;
          -  Shortening fraction &gt;= 27% by echocardiogram OR LVEF &gt;= 50% by gated radionuclide&#xD;
             study&#xD;
&#xD;
          -  Patients with a seizure disorder are eligible if on a nonenzyme-inducing&#xD;
             anticonvulsant and seizures are well controlled&#xD;
&#xD;
          -  No CNS toxicity &gt; grade 2&#xD;
&#xD;
          -  No serious intercurrent illnesses&#xD;
&#xD;
          -  No known hypersensitivity to E. coli-derived proteins, filgrastim (G-CSF), or any&#xD;
             component of the study drugs&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No known hypersensitivity to bortezomib, boron, or mannitol&#xD;
&#xD;
          -  No other concurrent chemotherapy or immunomodulating agents (including steroids)&#xD;
&#xD;
               -  Concurrent corticosteroids allowed for treatment or prophylaxis of anaphylactic&#xD;
                  reactions&#xD;
&#xD;
               -  No dexamethasone or aprepitant as an antiemetic&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No prior bortezomib or other proteasome inhibitors&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (4 weeks for nitrosoureas)&#xD;
&#xD;
          -  More than 14 days since prior investigational drugs&#xD;
&#xD;
          -  No concurrent enzyme inducing anticonvulsants that alter p450 metabolism, including&#xD;
             phenytoin, carbamazepine, phenobarbital, or other anticonvulsants&#xD;
&#xD;
               -  Benzodiazepine or gabapentin allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terzah Horton</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
  </removed_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 26, 2006</study_first_submitted>
  <study_first_submitted_qc>September 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2006</study_first_posted>
  <results_first_submitted>January 8, 2014</results_first_submitted>
  <results_first_submitted_qc>March 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2014</results_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Ifosfamide, Vinorelbine, Bortezomib)</title>
          <description>This was a single arm study that treated all patients with ifosfamide, vinorelbine, and bortezomib. Patients received ifosfamide IV (3000 mg/m2/day) continuously over days 1-4, vinorelbine ditartrate IV (25 mg/m2/dose) over 6-10 minutes on days 1 and 5, bortezomib IV (1.2 mg/m2/dose) on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment cycle repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy.&#xD;
ifosfamide: Given IV&#xD;
bortezomib: Given IV&#xD;
vinorelbine ditartrate: Given IV&#xD;
filgrastim: Given IV or SC</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Ifosfamide, Vinorelbine, Bortezomib)</title>
          <description>This was a single arm study that treated all patients with ifosfamide, vinorelbine, and bortezomib. Patients received ifosfamide IV (3000 mg/m2/day) continuously over days 1-4, vinorelbine ditartrate IV (25 mg/m2/dose) over 6-10 minutes on days 1 and 5, bortezomib IV (1.2 mg/m2/dose) on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment cycle repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy.&#xD;
ifosfamide: Given IV&#xD;
bortezomib: Given IV&#xD;
vinorelbine ditartrate: Given IV&#xD;
filgrastim: Given IV or SC</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.9" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response (CR)</title>
        <description>CR is defined as at least 80% reduction in the sum of the products of the perpendicular diameters of each of the nodal masses or return to normal size, along with negative nuclear medicine imaging.</description>
        <time_frame>After 2 cycles of treatment</time_frame>
        <population>Analysis population includes all patients evaluable for tumor response. Three enrolled patients are excluded: 1 ineligible, 1 who was removed from treatment after 1 dose of bortezomib, and 1 who received only 1/3 dose of bortezomib in cycle 1 and part of cycle 2 due to pharmacy error.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Ifosfamide, Vinorelbine, Bortezomib)</title>
            <description>This was a single arm study that treated all patients with ifosfamide, vinorelbine, and bortezomib. Patients received ifosfamide IV (3000 mg/m2/day) continuously over days 1-4, vinorelbine ditartrate IV (25 mg/m2/dose) over 6-10 minutes on days 1 and 5, bortezomib IV (1.2 mg/m2/dose) on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment cycle repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy.&#xD;
ifosfamide: Given IV&#xD;
bortezomib: Given IV&#xD;
vinorelbine ditartrate: Given IV&#xD;
filgrastim: Given IV or SC</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response (CR)</title>
          <description>CR is defined as at least 80% reduction in the sum of the products of the perpendicular diameters of each of the nodal masses or return to normal size, along with negative nuclear medicine imaging.</description>
          <population>Analysis population includes all patients evaluable for tumor response. Three enrolled patients are excluded: 1 ineligible, 1 who was removed from treatment after 1 dose of bortezomib, and 1 who received only 1/3 dose of bortezomib in cycle 1 and part of cycle 2 due to pharmacy error.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 3 or 4 Toxicity</title>
        <description>Grade 3 and 4 non-hematologic toxicity during protocol therapy. The number of patients that experience CTC Version 4 grade 3 or higher non-hematologic at any time during protocol therapy</description>
        <time_frame>4 weeks following completion of therapy</time_frame>
        <population>25 patients reported, 1 ineligible patient not included in adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Ifosfamide, Vinorelbine, Bortezomib)</title>
            <description>This was a single arm study that treated all patients with ifosfamide, vinorelbine, and bortezomib. Patients received ifosfamide IV (3000 mg/m2/day) continuously over days 1-4, vinorelbine ditartrate IV (25 mg/m2/dose) over 6-10 minutes on days 1 and 5, bortezomib IV (1.2 mg/m2/dose) on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment cycle repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy.&#xD;
ifosfamide: Given IV&#xD;
bortezomib: Given IV&#xD;
vinorelbine ditartrate: Given IV&#xD;
filgrastim: Given IV or SC</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or 4 Toxicity</title>
          <description>Grade 3 and 4 non-hematologic toxicity during protocol therapy. The number of patients that experience CTC Version 4 grade 3 or higher non-hematologic at any time during protocol therapy</description>
          <population>25 patients reported, 1 ineligible patient not included in adverse events.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
        <time_frame>After 2 cycles and 4 cycles</time_frame>
        <population>There were 23 patients evaluable after 2 cycles and 12 patients evaluable after 4 cycles. 1 patient was excluded after cycle 2 and cycle 4 due to pharmacy error. 2 patients were excluded after cycle 2 due to ineligibility and removal from treatment after 1 dose of bortezomib.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Ifosfamide, Vinorelbine, Bortezomib)</title>
            <description>This was a single arm study that treated all patients with ifosfamide, vinorelbine, and bortezomib. Patients received ifosfamide IV (3000 mg/m2/day) continuously over days 1-4, vinorelbine ditartrate IV (25 mg/m2/dose) over 6-10 minutes on days 1 and 5, bortezomib IV (1.2 mg/m2/dose) on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment cycle repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy.&#xD;
ifosfamide: Given IV&#xD;
bortezomib: Given IV&#xD;
vinorelbine ditartrate: Given IV&#xD;
filgrastim: Given IV or SC</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
          <population>There were 23 patients evaluable after 2 cycles and 12 patients evaluable after 4 cycles. 1 patient was excluded after cycle 2 and cycle 4 due to pharmacy error. 2 patients were excluded after cycle 2 due to ineligibility and removal from treatment after 1 dose of bortezomib.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Response Rate (After 2 cycles)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Response Rate (After 4 cycles)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Success Rate</title>
        <description>Induction success is defined as achieving CR or PR without a targeted primary toxicity. Primary toxicity includes toxic death (which is any death predominantly attributable to treatment-related toxicities or complications, occurring during or within one month of the completion of therapy), Non-hematologic grades 3 or 4 toxicities attributable to drug (with the specific exclusion of 1) Grade 3 or 4 nausea or vomiting, 2) grade 3 transaminases (AST/ALT) elevations which return to &lt; grade 1 prior to the time of the next treatment course, 3) grade 3 or 4 fever or infection, and 4) Grade 3 mucositis.) and Hematologic toxicity (Delay of &gt;2 weeks in the start of re-induction cycle 2 or in hematologic recovery after cycle 2 secondary to severe myelosuppression, infection, or sepsis.)</description>
        <time_frame>After 2 cycles and 4 cycles</time_frame>
        <population>There were 23 patients evaluable after 2 cycles and 12 patients evaluable after 4 cycles. 1 patient was excluded after cycle 2 and cycle 4 due to pharmacy error. 2 patients were excluded after cycle 2 due to ineligibility and removal from treatment after 1 dose of bortezomib.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Ifosfamide, Vinorelbine, Bortezomib)</title>
            <description>This was a single arm study that treated all patients with ifosfamide, vinorelbine, and bortezomib. Patients received ifosfamide IV (3000 mg/m2/day) continuously over days 1-4, vinorelbine ditartrate IV (25 mg/m2/dose) over 6-10 minutes on days 1 and 5, bortezomib IV (1.2 mg/m2/dose) on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment cycle repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy.&#xD;
ifosfamide: Given IV&#xD;
bortezomib: Given IV&#xD;
vinorelbine ditartrate: Given IV&#xD;
filgrastim: Given IV or SC</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Success Rate</title>
          <description>Induction success is defined as achieving CR or PR without a targeted primary toxicity. Primary toxicity includes toxic death (which is any death predominantly attributable to treatment-related toxicities or complications, occurring during or within one month of the completion of therapy), Non-hematologic grades 3 or 4 toxicities attributable to drug (with the specific exclusion of 1) Grade 3 or 4 nausea or vomiting, 2) grade 3 transaminases (AST/ALT) elevations which return to &lt; grade 1 prior to the time of the next treatment course, 3) grade 3 or 4 fever or infection, and 4) Grade 3 mucositis.) and Hematologic toxicity (Delay of &gt;2 weeks in the start of re-induction cycle 2 or in hematologic recovery after cycle 2 secondary to severe myelosuppression, infection, or sepsis.)</description>
          <population>There were 23 patients evaluable after 2 cycles and 12 patients evaluable after 4 cycles. 1 patient was excluded after cycle 2 and cycle 4 due to pharmacy error. 2 patients were excluded after cycle 2 due to ineligibility and removal from treatment after 1 dose of bortezomib.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Induction Success Rate (After 2 cycles)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induction Success Rate (After 4 cycles)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Successful PBSC Harvest</title>
        <description>Success is defined as the ability to harvest 2x10^6 CD34+ cells/kg within 5 collection days.</description>
        <time_frame>After 2 cycles</time_frame>
        <population>Analysis population includes all patients evaluable after cycle 2. Six enrolled patients are excluded: 1 ineligible, 1 who was removed from treatment after 1 dose of bortezomib, and 1 who received only 1/3 dose of bortezomib in cycle 1 and part of cycle 2 due to pharmacy error, 3 who did not have recorded data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Ifosfamide, Vinorelbine, Bortezomib)</title>
            <description>This was a single arm study that treated all patients with ifosfamide, vinorelbine, and bortezomib. Patients received ifosfamide IV (3000 mg/m2/day) continuously over days 1-4, vinorelbine ditartrate IV (25 mg/m2/dose) over 6-10 minutes on days 1 and 5, bortezomib IV (1.2 mg/m2/dose) on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment cycle repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy.&#xD;
ifosfamide: Given IV&#xD;
bortezomib: Given IV&#xD;
vinorelbine ditartrate: Given IV&#xD;
filgrastim: Given IV or SC</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Successful PBSC Harvest</title>
          <description>Success is defined as the ability to harvest 2x10^6 CD34+ cells/kg within 5 collection days.</description>
          <population>Analysis population includes all patients evaluable after cycle 2. Six enrolled patients are excluded: 1 ineligible, 1 who was removed from treatment after 1 dose of bortezomib, and 1 who received only 1/3 dose of bortezomib in cycle 1 and part of cycle 2 due to pharmacy error, 3 who did not have recorded data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biological Markers</title>
        <description>Assessing baseline NF-kB protein levels in tumor tissue</description>
        <time_frame>Before, during, and after treatment</time_frame>
        <population>Corresponding data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Ifosfamide, Vinorelbine, Bortezomib)</title>
            <description>This was a single arm study that treated all patients with ifosfamide, vinorelbine, and bortezomib. Patients received ifosfamide IV (3000 mg/m2/day) continuously over days 1-4, vinorelbine ditartrate IV (25 mg/m2/dose) over 6-10 minutes on days 1 and 5, bortezomib IV (1.2 mg/m2/dose) on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment cycle repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy.&#xD;
ifosfamide: Given IV&#xD;
bortezomib: Given IV&#xD;
vinorelbine ditartrate: Given IV&#xD;
filgrastim: Given IV or SC</description>
          </group>
        </group_list>
        <measure>
          <title>Biological Markers</title>
          <description>Assessing baseline NF-kB protein levels in tumor tissue</description>
          <population>Corresponding data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>25 patients reported, 1 ineligible patient not included in adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Ifosfamide, Vinorelbine, Bortezomib)</title>
          <description>This was a single arm study that treated all patients with ifosfamide, vinorelbine, and bortezomib. Patients received ifosfamide IV (3000 mg/m2/day) continuously over days 1-4, vinorelbine ditartrate IV (25 mg/m2/dose) over 6-10 minutes on days 1 and 5, bortezomib IV (1.2 mg/m2/dose) on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment cycle repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy.&#xD;
ifosfamide: Given IV&#xD;
bortezomib: Given IV&#xD;
vinorelbine ditartrate: Given IV&#xD;
filgrastim: Given IV or SC</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>352-273-0567</phone>
      <email>resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

